La vendita allo scoperto per PROCEPT BioRobotics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di PROCEPT BioRobotics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

PROCEPT BioRobotics (NASDAQ:PRCT) Azioni, Report sulle vendite allo scoperto

PROCEPT BioRobotics

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Long Ideas

News

Markets

Media

Trading Ideas

PRCT

Jim Cramer elogia Target per il suo rendimento del 3% e risultati finanziari eccellenti: ecco perché è un&#39;opportunità imperdibile!

Jim Cramer elogia questo titolo: &#34;Il rendimento del 3% è fantastico!&#34;

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics Corp

Lions Gate Entertainment Corporation Class B Non-Voting Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.65) by 33.85 percent. The company reported quarterly sales of $948.600 million which missed the analyst consensus estimate of $956.789 million by 0.86 percent. This is a 6.63 percent decrease over sales of $1.016 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

Lions Gate Entertainment Corporation Class B Non-Voting Shares Q2 2025 Adj. EPS $(0.43) Beats $(0.65) Estimate, Sales $948.600M Miss $956.789M Estimate

Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.58) by 27.59 percent. The company reported quarterly sales of $2.17 million which beat the analyst consensus estimate of $648.50 thousand by 234.62 percent. This is a 134.85 percent increase over sales of $924.00 thousand the same period last year.

DNTH

Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate

89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.64) by 117.19 percent. This is a 208.89 percent decrease over losses of $(0.45) per share from the same period last year.

ETNB

89bio Q3 EPS $(1.39) Misses $(0.64) Estimate

WIIM

Agilon Health shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 60 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $641.141 thousand which beat the analyst consensus estimate of $375.000 thousand by 70.97 percent. This is a 73.91 percent decrease over sales of $2.457 million the same period last year.

CODX

Co-Diagnostics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $641.141K Beat $375.000K Estimate

ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $171.33 million which beat the analyst consensus estimate of $160.42 million by 6.80 percent. This is a 43.96 percent increase over sales of $119.01 million the same period last year.

ACVA

ACV Auctions Q3 EPS $(0.10) Beats $(0.11) Estimate, Sales $171.33M Beat $160.42M Estimate

Retail Sales

PRCH

Porch Group Announced That It Lowered Its FY24 Sales Guidance From $450M-470M to $440M-455M

Guidance

SGHT

Sight Sciences Sees FY24 Revenue $81M-$83M Vs $82.16M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) raises FY2024 sales outlook from $318.00 million-325.00 million to $322.00 million-326.00 million.

Eventbrite Raises FY2024 Sales Guidance from $318.00M-325.00M to $322.00M-326.00M  VS Est.322.03M

Stock Split

ANET

Arista Approved Four-For-One Forward Stock Split

RIGL

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $231.358 million which beat the analyst consensus estimate of $223.537 million by 3.50 percent. This is a 5.44 percent increase over sales of $219.419 million the same period last year.

CARG

CarGurus Q3 2024 Adj. EPS $0.45 Beats $0.42 Estimate, Sales $231.358M Beat $223.537M Estimate

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively.

ADMA

ADMA Biologics FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively

BSLK

Bolt Projects Holdings Q3 EPS $0.32

UPLD

Upland Software shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 200 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $161.23 million which missed the analyst consensus estimate of $162.25 million by 0.63 percent. This is a 37.44 percent decrease over sales of $257.73 million the same period last year.

GDEN

Golden Entertainment Q3 EPS $0.18 Beats $0.10 Estimate, Sales $161.23M Miss $162.25M Estimate

aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent.

ATYR

aTyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate

Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(0.83) by 63.86 percent. This is a 85.44 percent increase over losses of $(9.34) per share from the same period last year.

SYRE

Spyre Therapeutics Q3 EPS $(1.36) Misses $(0.83) Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) raises FY2024 Adj EPS guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 analyst estimate. Narrows FY2024 sales outlook from $835.00 million-845.00 million to $837.00 million-843.00 million vs $841.44 million estimate.

MYGN

Myriad Genetics Raises FY2024 Adj EPS Guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 Est; Narrows FY2024 Sales Guidance from $835.00M-845.00M to $837.00M-843.00M vs $841.44M Est

LCUT

Lifetime Brands shares are trading lower after the company reported worse-than-expected Q3 financial results and lowered its FY24 guidance and Q4 EPS guidance.

Biggest stock movers Monday: DJT, crypto stocks, and more

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The associated price target rem...

Strong Financial Performance and Growth Potential Drive Buy Rating for PROCEPT BioRobotics

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) will offer 90M shares of c...

Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz

PROCEPT BioRobotics announces proposed offering of common stock

Procept BioRobotics (PRCT) announced the commencement of an underwritten public offering of $175M of shares of its common stock. A selling stockhol...

Procept BioRobotics announces $175M common stock offering

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on PROCEPT BioRobotics (PRCT – Research Report). The company's sh...

BTIG Remains a Hold on PROCEPT BioRobotics (PRCT)

PROCEPT BioRobotics (PRCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mike Kratky ...

Strong Future Potential and Resilience: PROCEPT BioRobotics as a Compelling Hypergrowth MedTech Story

The deal priced below last closing price of $96.69. BofA, Piper Sandler and Morgan Stanley are acting as joint book running managers for the offeri...

Procept BioRobotics 1.92M share Spot Secondary priced at $91.00

Truist raised the firm's price target on Procept BioRobotics (PRCT) to $105 from $95 and keeps a Buy rating on the shares. After a "strong" Q3 earn...

Comments

PROCEPT BioRobotics

Vendite allo scoperto

PROCEPT BioRobotics (NASDAQ:PRCT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO